BT-001 (EN)

Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors

20210301 - Transgene BT-001 FPI - EN

By Lucie Larguier|2021-02-26T18:04:43+01:00March 1st, 2021|BT-001 (EN), Press release|Comments Off

Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors

20210119 - ANSM Approval BT-001 EN

By nh|2021-01-18T16:39:17+01:00January 19th, 2021|BT-001, BT-001 (EN), Invir.IO, Press release|Comments Off

Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors

20201221 - CTA Approval BT-001 - EN

By nh|2020-12-18T15:09:42+01:00December 21st, 2020|BT-001, BT-001 (EN), Press release|Comments Off

Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201109 Transgene BioInvent_SITC BT001_EN

By nh|2020-12-09T17:51:03+01:00November 9th, 2020|BT-001, BT-001 (EN), Invir.IO, Press release|Comments Off

BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

Poster BT-001 M. Semmrich et al. SITC 2020 Download the [...]

By Lucie Larguier|2020-12-09T17:52:54+01:00November 9th, 2020|BT-001 (EN), Invir.IO, Publication|Comments Off

Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting

20201015 - BT-001_SITC poster EN

By nh|2020-10-14T16:19:05+02:00October 15th, 2020|BT-001, BT-001 (EN), Press release|Comments Off

BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment

AACR2020-BT-001 Jean-Baptiste Marchand et al. AACR 2020 Download the poster [...]

By alcyon|2020-06-22T18:32:23+02:00June 22nd, 2020|BT-001, BT-001 (EN), Invir.IO, Publication|Comments Off